Relevance of DNA damage repair in the management of prostate cancer

Recent insights into the genomic aberrations that underlie and drive prostate cancer have redoubled efforts to molecularly stratify treatments based on predictive markers. Approximately 23% of patients with metastatic castration-resistant prostate cancer exhibit somatic and/or germline aberrations in genes implicated in DNA repair, such as BRCA2, BRCA1, ATM, CHEK2 and PALB2, as well as mismatch repair (MMR) genes. At least 10% of men with advanced disease have germline mutations in DNA repair genes (DRG).
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research